The State of Radiopharmaceuticals 2026 is an 84-page, systems-level intelligence report on the structural forces governing the only pharmaceutical modality bound by quantum mechanics - including isotope supply fragility, geopolitical chokepoints, manufacturing reality, the alpha transition, talent scarcity, and the five mispricings distorting how the market values this sector. Built for pharma executives, investors, CDMO operators, and clinical leaders, it shows where execution risk is hiding, where infrastructure determines the TAM, and which strategic architectures are most likely to win.